Yabao Pharmaceutical (600351.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 257 million yuan, a year-on-year increase of 19.29%.

Zhitong Finance APP News, Yabao Pharmaceutical (600351.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 1.663 billion yuan, a year-on-year decrease of 2.67%; net profit attributable to the parent company was 257 million yuan, a year-on-year increase of 19.29%; net profit after deducting non-recurring gains and losses was 258 million yuan, a year-on-year increase of 30.47%; basic earnings per share were 0.3708 yuan.